Freienbach/Mumbai – EffRx Pharmaceuticals from the canton of Schwyz and Lupin have signed an agreement for the joint commercialization of an osteoporosis medication. The agreement focuses on introducing the product to Vietnam and the Philippines.

EffRx, a Freienbach-based pharmaceutical company with a particular focus on medications that treat musculoskeletal and rare diseases, is set to enter the market in Vietnam and the Philippines together with global Indian pharmaceutical company Lupin Limited. According to a press release the two companies will distribute a medicine called Binosto, a buffered soluble alendronate indicated for the treatment of postmenopausal osteoporosis. EffRx says the product, which is authorized for use in Asia, Europe, the Middle East and the U.S., has fewer upper gastrointestinal side effects than other alendronate medications.

“We are delighted to announce the partnership with Lupin to further expand the footprint of Binosto,” says Lorenzo Bosisio, CEO of EffRx Pharmaceuticals. “With their well-established expertise and presence in Vietnam and the Philippines, Lupin is the partner of choice to make Binosto widely available to women in these countries”.

“We are excited about our collaboration with EffRx Pharmaceuticals, which will empower postmenopausal women with this innovative healthcare solution. Introducing Binosto to Vietnam and Philippines signifies our commitment to advancing healthcare, further exemplifying Lupin’s global commitment to improving health outcomes,” explains Dr Fabrice Egros, President of Corporate Development and Growth Markets at Lupin. ce/ww